Patient Specific Compounding - Mpje

1. Which compounding category may produce without patient-specific prescriptions but must meet cGMP requirements?

   503B outsourcing facilities (non-patient-specific) under cGMP. Section 503B allows outsourcing facilities to compound in bulk without patient-specific orders, provided they follow current good manufacturing practices for quality and safety.

2. Which requirement must be met before compounding if the order requests office stock for future patients?

   Do not compound as 503A; requires 503B or patient-specific prescriptions. Federal law prohibits 503A pharmacies from compounding office stock without patient-specific orders to maintain distinctions from manufacturing.

3. Find and correct the issue: A 503A pharmacy compounds a product in advance for no named patient. What is the correction?

   Obtain patient-specific prescriptions or use a 503B outsourcing facility. Anticipatory compounding without patient-specific orders violates 503A rules, requiring redirection to compliant practices under federal law.

4. What validation is required when a compounded prescription uses a nonstandard abbreviation or unclear directions?

   Clarify with prescriber and document the clarification before compounding. Clarification is required by pharmacy laws and USP guidelines to resolve ambiguities, ensuring accurate and safe compounding practices.

5. What strength expression requirement must be met to validate a compounded prescription formulation request?

   Strength/concentration must be clearly specified (e.g., mg/mL or %). Clear strength notation is mandated by USP <795> and <797> to ensure precise formulation and dosing accuracy in compounded preparations.

6. Identify the key clinical appropriateness check required before compounding for a specific patient.

   Confirm indication and patient-specific need; assess therapy appropriateness. Pharmacists must evaluate clinical need per professional standards and USP guidelines to justify compounding and ensure therapeutic appropriateness for the patient.

7. What dosing direction element must be present to validate that a compounded prescription is complete for patient use?

   Sig: route, dose, frequency, and duration or intended use instructions. Complete sig directions are mandated by law to provide clear guidance on safe and effective use, preventing misuse or errors in administration.

8. Find the missing element: Rx has patient, drug, directions, quantity, but no prescriber identifier. What must be added?

   Prescriber identification (name/credentials and contact information). Prescriber identification is a core prescription requirement under state laws to verify authority and facilitate communication for incomplete orders.

9. What is the required element that distinguishes a prescription from a medication order request in compounding workflows?

   A valid prescriber authorization for a specific patient and drug. Prescriber authorization ensures the compounded drug is legally intended for a named patient, distinguishing it from bulk orders under compounding regulations.

10. What allergy-related validation must be completed before compounding a patient-specific preparation?

    Verify patient allergies and excipient sensitivities against all ingredients. Allergy verification is a critical safety step under pharmacy practice standards to avoid adverse reactions from active ingredients or excipients in the formulation.

11. Identify the required validation step when a compounded prescription includes a controlled substance ingredient.

    Verify controlled substance legitimacy and comply with CS prescribing rules. Controlled substance validation ensures compliance with DEA regulations, including legitimate medical purpose and prescriber registration checks.

12. Identify the validation outcome: Prescription requests 'dispense 3 bottles' but no bottle size is defined. What is required?

    Clarify total quantity or container size to determine amount to compound. Undefined quantities prevent precise compounding, requiring clarification to align with the prescribed therapeutic needs and avoid waste or shortages.

13. What is required to validate that a compounded prescription is authorized for dispensing when not e-prescribed?

    A valid prescriber signature per applicable state/federal rules. Signature requirements under state pharmacy laws and DEA rules authenticate non-electronic prescriptions, confirming prescriber intent and legal compliance.

14. Which interaction check is required when validating a compounded prescription before preparation?

    Screen for drug–drug, drug–disease, and drug–allergy interactions. Interaction screening is required as part of drug utilization review to mitigate risks and promote patient safety before compounding.

15. Which compounding category requires a patient-specific prescription before preparation under federal law?

    503A traditional compounding requires a patient-specific prescription. Federal law under FD&C Act Section 503A mandates individualized prescriptions to exempt traditional compounding from full drug approval processes.

16. Identify the validation outcome: Order states 'compound cream as usual' with no strength. What is required before compounding?

    Clarify and obtain the exact strength/concentration from prescriber. Vague orders violate prescription clarity standards, necessitating prescriber confirmation to ensure accurate and safe compounded formulation.

17. Which documentation must be created or referenced to validate the formula for a patient-specific compounded preparation?

    A master formulation record (or equivalent standardized formula reference). USP <795> and <797> require a master record to standardize ingredients, procedures, and quality controls for reproducible compounding.

18. Which directive on the prescription must be present to determine the compounded preparation quantity to dispense?

    The quantity to dispense (or total volume/amount to compound). Quantity specification is essential per prescription requirements to calculate the exact amount needed for the patient's prescribed therapy duration.

19. Which element must be present to validate refills for a compounded prescription when refills are intended?

    Number of refills authorized (or explicit 'no refills'). Refill authorization is stipulated in prescription regulations to control dispensing limits and ensure ongoing prescriber oversight of therapy.

20. What prescriber information must be present to validate a patient-specific compounded prescription?

    Prescriber name, credentials, and contact information. Prescription validity under state and federal laws necessitates prescriber details to authenticate the order and enable necessary clarifications or verifications.

21. What is the required validation when a compounded prescription requests an unusually high dose or volume?

    Perform clinical plausibility check and confirm with prescriber if needed. Plausibility checks are part of pharmacists' professional responsibility to prevent errors or harm from atypical dosing in compounded medications.

22. Which route/form requirement must be validated to ensure the correct compounded dosage form is prepared?

    Dosage form and intended route of administration must be specified. Specification of form and route is necessary per compounding standards to select appropriate ingredients and methods for safe delivery.

23. What record must be generated for each patient-specific compounded prescription to document the actual compounding?

    A compounding record (batch/preparation record) for that dispensed lot. Compounding records are mandated by USP standards to document specific preparation details, enabling traceability and quality verification for each batch.

24. Identify the minimum patient identifiers that should appear on a patient-specific compounded prescription.

    Patient name plus at least one additional identifier (e.g., DOB). Patient safety standards, such as those from The Joint Commission, require multiple identifiers to prevent misidentification and ensure accurate dispensing of compounded preparations.

25. Which date element is required to validate a patient-specific compounded prescription for legal processing?

    Date of issuance (date written). Issuance date is required under federal and state laws to establish the prescription's timeliness and validity for filling or refilling.

Study these flashcards